Prostate Cancer Reports


Volume 2 Number 3
 March 2014

Home > Prostate Cancer Reports > Volume 2 - Year 2014, Number 3, March 2014

CONTENTS


Case reports
Diagnosis and evaluation
Etiology and pathogenesis
Integrative medicine
Nomograms
Prognosis and outcome
Staging
Treatment



CASE REPORTS


Acar O, Esen T, Bavbek S, Peker O, Musaoğlu A.
Port site and peritoneal metastases after robot-assisted radical prostatectomy.
Int J Surg Case Rep. 2014;5(3):131-4. doi: 10.1016/j.ijscr.2014.01.010. Epub 2014 Jan 24.
Abstract | Full text | Related citations


Cohen PR.
Melanoma of Non-Sun Exposed Skin in a Man with Previous Prostate Cancer: Recognition of a Recently Confirmed Association.
Dermatol Ther (Heidelb). 2014 Feb 22. [Epub ahead of print]
Abstract | Full text | Related citations

DIAGNOSIS AND EVALUATION


Ceylan C, Doluoglu OG, Aglamis E, Baytok O.
Comparison of 8, 10, 12, 16, 20 cores prostate biopsies in the determination of prostate cancer and the importance of prostate volume.
Can Urol Assoc J. 2014 Jan-Feb;8(1-2):E81-5. doi: 10.5489/cuaj.510.
Abstract | Full text | Related citations


Chondrogiannis S, Marzola MC, Ferretti A, Grassetto G, Maffione AM, Rampin L, Fanti S, Giammarile F, Rubello D.
Is the detection rate of 18F-choline PET/CT influenced by androgen-deprivation therapy?
Eur J Nucl Med Mol Imaging. 2014 Feb 25. [Epub ahead of print]
Abstract | Related citations


Kim CK, Park SY, Park JJ, Park BK.
Diffusion-weighted MRI as a predictor of extracapsular extension in prostate cancer.
AJR Am J Roentgenol. 2014 Mar;202(3):W270-6. doi: 10.2214/AJR.13.11333.
Abstract | Related citations


Kim JY, Kim SH, Kim YH, Lee HJ, Kim MJ, Choi MS.
Low-Risk Prostate Cancer: The Accuracy of Multiparametric MR Imaging for Detection.
Radiology. 2014 May;271(2):435-44. doi: 10.1148/radiol.13130801. Epub 2014 Jan 23.
Abstract | Related citations


Rud E, Baco E, Lien D, Klotz D, Eggesbř HB.
Detection of radiorecurrent prostate cancer using diffusion-weighted imaging and targeted biopsies.
AJR Am J Roentgenol. 2014 Mar;202(3):W241-6. doi: 10.2214/AJR.12.10483.
Abstract | Related citations

ETIOLOGY AND PATHOGENESIS


de Oliveira Barros EG, Palumbo A Jr, Mello PL, de Mattos RM, da Silva JH, Pontes B, Viana NB, do Amaral RF, Lima FR, da Costa NM, Palmero CY, Miranda-Alves L, Takiya CM, Nasciutti LE.
The reciprocal interactions between astrocytes and prostate cancer cells represent an early event associated with brain metastasis.
Clin Exp Metastasis. 2014 Feb 1. [Epub ahead of print]
Abstract | Related citations


Lobaccaro JM, Trousson A.
Environmental estrogen exposure during fetal life: a time bomb for prostate cancer.
Endocrinology. 2014 Mar;155(3):656-8. doi: 10.1210/en.2014-1057.
Abstract | Full text | Related citations


Prins GS, Hu WY, Shi GB, Hu DP, Majumdar S, Li G, Huang K, Nelles JL, Ho SM, Walker CL, Kajdacsy-Balla A, van Breemen RB.
Bisphenol A promotes human prostate stem-progenitor cell self-renewal and increases in vivo carcinogenesis in human prostate epithelium.
Endocrinology. 2014 Mar;155(3):805-17. doi: 10.1210/en.2013-1955. Epub 2014 Jan 1.
Abstract | Related citations

INTEGRATIVE MEDICINE



Bhindi B, Locke J, Alibhai SM, Kulkarni GS, Margel DS, Hamilton RJ, Finelli A, Trachtenberg J, Zlotta AR, Toi A, Hersey KM, Evans A, van der Kwast TH, Fleshner NE.
Dissecting the Association Between Metabolic Syndrome and Prostate Cancer Risk: Analysis of a Large Clinical Cohort.
Eur Urol. 2014 Feb 14. pii: S0302-2838(14)00125-0. doi: 10.1016/j.eururo.2014.01.040. [Epub ahead of print]
Abstract | Related citations


Kristal AR, Darke AK, Morris JS, Tangen CM, Goodman PJ, Thompson IM, Meyskens FL Jr, Goodman GE, Minasian LM, Parnes HL, Lippman SM, Klein EA.
Baseline selenium status and effects of selenium and vitamin e supplementation on prostate cancer risk.
J Natl Cancer Inst. 2014 Mar 1;106(3):djt456. doi: 10.1093/jnci/djt456. Epub 2014 Feb 22.
Abstract | Related citations



Ming DS, Pham S, Deb S, Chin MY, Kharmate G, Adomat H, Beheshti EH, Locke J, Guns ET.
Pomegranate extracts impact the androgen biosynthesis pathways in prostate cancer models in vitro and in vivo.
J Steroid Biochem Mol Biol. 2014 Feb 22;143C:19-28. doi: 10.1016/j.jsbmb.2014.02.006. [Epub ahead of print]
Abstract | Related citations

NOMOGRAMS

Hinev AI, Anakievski D, Kolev NH, Hadjiev VI.
Validation of nomograms predicting lymph node involvement in patients with prostate cancer undergoing extended pelvic lymph node dissection.
Urol Int. 2014;92(3):300-5. doi: 10.1159/000354323. Epub 2014 Jan 25.
Abstract | Related citations

PROGNOSIS AND OUTCOME


Bagshaw H, Ruth K, Horwitz EM, Chen DY, Buyyounouski MK.
Does family history of prostate cancer affect outcomes following radiotherapy?
Radiother Oncol. 2014 Feb;110(2):229-34. doi: 10.1016/j.radonc.2013.11.014. Epub 2014 Feb 20.
Abstract | Related citations


Joniau S, Briganti A, Gontero P, Gandaglia G, Tosco L, Fieuws S, Tombal B, Marchioro G, Walz J, Kneitz B, Bader P, Frohneberg D, Tizzani A, Graefen M, van Cangh P, Karnes RJ, Montorsi F, Van Poppel H, Spahn M; European Multicenter Prostate Cancer Clinical and Translational Research Group (EMPaCT).
Stratification of High-risk Prostate Cancer into Prognostic Categories: A European Multi-institutional Study.
Eur Urol. 2014 Jan 25. pii: S0302-2838(14)00071-2. doi: 10.1016/j.eururo.2014.01.020. [Epub ahead of print]
Abstract | Related citations


Oncologic outcomes

Ponholzer A, Trubel S, Schramek P, Wimpissinger F, Feichtinger H, Springer C, Wehrberger C, Fischereder K, Pummer K, Martini T, Mayr R, Pycha A, Madersbacher S.
Prostate cancer at the peripheral end of prostate biopsy specimen predicts increased risk of positive resection margin after radical prostatectomy: results of a prospective multi-institutional study.
World J Urol. 2014 Feb 8. [Epub ahead of print]
Abstract | Related citations


Localized PCa

Kimura K, Tsuzuki T, Kato M, Saito AM, Sassa N, Ishida R, Hirabayashi H, Yoshino Y, Hattori R, Gotoh M.
Prognostic value of intraductal carcinoma of the prostate in radical prostatectomy specimens.
Prostate. 2014 May;74(6):680-7. doi: 10.1002/pros.22786. Epub 2014 Jan 31.
Abstract | Related citations


Silberstein JL, Poon SA, Sjoberg DD, Maschino AC, Vickers AJ, Bernie A, Konety BR, Kelly WK, Eastham JA.
Long term oncologic outcomes of a Phase II trial of neoadjuvant chemohormonal therapy followed by radical prostatectomy for patients with clinically localized, high-risk prostate cancer.
BJU Int. 2014 Feb 19. doi: 10.1111/bju.12676. [Epub ahead of print]
Abstract | Related citations


Locally advanced PCa

Pepe P, Improta G, Fraggetta F, Emmanuele C, Simeon V, Dibenedetto G, Colecchia M, Aragona F.
PSA nadir and outcome in 100 patients with pT3b prostate cancer.
Anticancer Res. 2014 Feb;34(2):937-41.
Abstract | Related citations


Survival

Lo AC, Morris WJ, Lapointe V, Hamm J, Keyes M, Pickles T, McKenzie M, Spadinger I.
Prostate-specific antigen at 4 to 5 years after low-dose-rate prostate brachytherapy is a strong predictor of disease-free survival.
Int J Radiat Oncol Biol Phys. 2014 Jan 1;88(1):87-93. doi: 10.1016/j.ijrobp.2013.10.010.
Abstract | Related citations


Ma X, Xiao Z, Li X, Wang F, Zhang J, Zhou R, Wang J, Liu L.
Prognostic role of circulating tumor cells and disseminated tumor cells in patients with prostate cancer: a systematic review and meta-analysis.
Tumour Biol. 2014 Feb 22. [Epub ahead of print]
Abstract | Related citations


Morgan CJ, Oh WK, Naik G, Galsky MD, Sonpavde G.
Impact of prednisone on toxicities and survival in metastatic castration-resistant prostate cancer: A systematic review and meta-analysis of randomized clinical trials.
Crit Rev Oncol Hematol. 2014 Jun;90(3):253-261. doi: 10.1016/j.critrevonc.2013.12.001. Epub 2014 Feb 2.
Abstract | Full text | Related citations


Tollefson MK, Karnes RJ, Kwon ED, Lohse CM, Rangel LJ, Mynderse LA, Cheville JC, Sebo TJ.
Prostate cancer Ki-67 (MIB-1) expression, perineural invasion, and gleason score as biopsy-based predictors of prostate cancer mortality: the Mayo model.
Mayo Clin Proc. 2014 Mar;89(3):308-18. doi: 10.1016/j.mayocp.2013.12.001. Epub 2014 Jan 31.
Abstract | Related citations

RECURRENCE



Izard JP, True LD, May P, Ellis WJ, Lange PH, Dalkin B, Lin DW, Schmidt RA, Wright JL.
Prostate cancer that is within 0.1 mm of the surgical margin of a radical prostatectomy predicts greater likelihood of recurrence.
Am J Surg Pathol. 2014 Mar;38(3):333-8. doi: 10.1097/PAS.0000000000000162.
Abstract | Related citations



Milonas D, Kinčius M, Skulčius G, Matjošaitis AJ, Gudinavičienė I, Jievaltas M.
Evaluation of D'Amico criteria for low-risk prostate cancer.
Scand J Urol. 2014 Feb 12. [Epub ahead of print]
Abstract | Related citations


Rřder MA, Kawa S, Scheike T, Toft BG, Hansen JB, Brasso K, Vainer B, Iversen P.
Non-apical positive surgical margins after radical prostatectomy for pT2 prostate cancer is associated with the highest risk of recurrence.
J Surg Oncol. 2014 Jun;109(8):818-22. doi: 10.1002/jso.23573. Epub 2014 Feb 13.
Abstract | Related citations


Wen YC, Chen WY, Lee WJ, Yang SF, Lee LM, Chien MH.
Snail as a potential marker for predicting the recurrence of prostate cancer in patients at stage T2 after radical prostatectomy.
Clin Chim Acta. 2014 Apr 20;431:169-73. doi: 10.1016/j.cca.2014.01.036. Epub 2014 Feb 7.
Abstract | Related citations


Zaorsky NG, Yamoah K, Thakur ML, Trabulsi EJ, Showalter TN, Hurwitz MD, Dicker AP, Den RB.
A paradigm shift from anatomic to functional and molecular imaging in the detection of recurrent prostate cancer.
Future Oncol. 2014 Feb;10(3):457-74. doi: 10.2217/fon.13.196.
Abstract | Related citations

SCREENING AND EARLY DETECTION


Ploussard G, Nicolaiew N, Mongiat-Artus P, Terry S, Allory Y, Vacherot F, Abbou CC, Desgrandchamps F, Salomon L, de la Taille A.
Left lobe of the prostate during clinical prostate cancer screening: the dark side of the gland for right-handed examiners.
Prostate Cancer Prostatic Dis. 2014 Jun;17(2):157-62. doi: 10.1038/pcan.2014.2. Epub 2014 Feb 11.
Abstract | Related citations

STAGING

Danneman D, Drevin L, Robinson D, Stattin P, Egevad L
Gleason Inflation 1998-2011. A Registry Study of 97 168 Men.
BJU Int. 2014 Feb 19. doi: 10.1111/bju.12671. [Epub ahead of print]
Abstract | Related citations

TREATMENT

Treatment overviews

Lou DY, Fong L.
Neoadjuvant therapy for localized prostate cancer: Examining mechanism of action and efficacy within the tumor.
Urol Oncol. 2014 Feb 1. pii: S1078-1439(13)00500-0. doi: 10.1016/j.urolonc.2013.12.001. [Epub ahead of print]
Abstract | Related citations


Omlin A, Pezaro C, Gillessen Sommer S.
Sequential use of novel therapeutics in advanced prostate cancer following docetaxel chemotherapy.
Ther Adv Urol. 2014 Feb;6(1):3-14.
Abstract | Full text | Related citations


Turner B, Drudge-Coates L.
Pharmacological treatment of patients with advanced prostate cancer.
Nurs Stand. 2014 Feb 5;28(23):44-8. doi: 10.7748/ns2014.02.28.23.44.e7823.
Abstract | Related citations


Zhang K, Zhang X.
Treatment strategies for locally advanced prostate cancer.
Chin Med J (Engl). 2014;127(5):957-60.
Abstract | Full text | Related citations


Zustovich F, Fabiani F.
Therapeutic opportunities for castration-resistant prostate cancer patients with bone metastases.
Crit Rev Oncol Hematol. 2014 Jan 17. pii: S1040-8428(14)00013-4. doi: 10.1016/j.critrevonc.2014.01.003. [Epub ahead of print]
Abstract | Full text | Related citations


Special topics

Statins



Platz EA, Tangen CM, Goodman PJ, Till C, Parnes HL, Figg WD, Albanes D, Neuhouser ML, Klein EA, Lucia MS, Thompson IM Jr, Kristal AR.
Statin Drug Use Is Not Associated with Prostate Cancer Risk in Men Who Are Regularly Screened.
J Urol. 2014 Feb 8. pii: S0022-5347(14)00195-5. doi: 10.1016/j.juro.2014.01.095. [Epub ahead of print]
Abstract | Related citations


First-line treatment

Localized PCa

Araki M, Jeong W, Park SY, Lee YH, Nasu Y, Kumon H, Hong SJ, Rha KH.
Robot-assisted radical prostatectomy: modified ultradissection reduces pT2 positive surgical margins on the bladder neck.
Acta Med Okayama. 2014 Feb;68(1):35-41.
Abstract | Full text | Related citations


Bhattasali O, Chen LN, Woo J, Park JW, Kim JS, Moures R, Yung T, Lei S, Collins BT, Kowalczyk K, Suy S, Dritschilo A, Lynch JH, Collins SP.
Patient-reported outcomes following stereotactic body radiation therapy for clinically localized prostate cancer.
Radiat Oncol. 2014 Feb 11;9:52. doi: 10.1186/1748-717X-9-52.
Abstract | Full text | Related citations



Gómez-Veiga F, Portela-Pereira P, Cozar-Olmo JM, Ahmed H, Moore C, Dickinson L, Algaba F, Izquierdo L, Alcaraz Asensio A, Martinez-Breijo S, Emberton M.
Focal Therapy for Prostate Cancer. Rationale, Indications and Selection.
Actas Urol Esp. 2014 Feb 17. pii: S0210-4806(14)00004-7. doi: 10.1016/j.acuro.2013.12.005. [Epub ahead of print]
Abstract | Related citations


Rexer H.
[First-line therapy for low-risk prostate cancer: prospective phase II study of focal therapy (hemiablation) of the prostate with high intensity focused ultrasound (HIFU) in patients suitable for "Active Surveillance" (AP 68/11 of the AUO)].
Urologe A. 2014 Mar;53(3):382-3. doi: 10.1007/s00120-014-3431-6.
Abstract | Related citations


High-risk PCa

Gandaglia G, Karakiewicz PI, Briganti A, Trinh QD, Schiffmann J, Tian Z, Kim SP, Nguyen PL, Graefen M, Montorsi F, Sun M, Abdollah F.
Intensity-modulated radiation therapy leads to survival benefit only in patients with high-risk prostate cancer: a population-based study.
Ann Oncol. 2014 May;25(5):979-86. doi: 10.1093/annonc/mdu087. Epub 2014 Feb 20.
Abstract | Related citations


Locally advanced PCa

Gözen AS, Akin Y, Ates M, Hruza M, Rassweiler J.
Impact of Laparoscopic Radical Prostatectomy on Clinical T3 Prostate Cancer: Experience of Single Center With Long Term Follow-Up.
BJU Int. 2014 Feb 27. doi: 10.1111/bju.12710. [Epub ahead of print]
Abstract | Related citations


Shilkrut M, McLaughlin PW, Merrick GS, Vainshtein JM, Hamstra DA.
Treatment Outcomes in Very High-risk Prostate Cancer Treated by Dose-escalated and Combined-Modality Radiation Therapy.
Am J Clin Oncol. 2014 Feb 10. [Epub ahead of print]
Abstract | Related citations


Second-line-treatment

Localized PCa



Park JS, Park W, Pyo HR, Park BK, Park SY, Choi HY, Lee HM, Jeon SS, Seo SI, Jeong BC, Jeon HG.
Suggestion for the prostatic fossa clinical target volume in adjuvant or salvage radiotherapy after a radical prostatectomy.
Radiother Oncol. 2014 Feb;110(2):240-4. doi: 10.1016/j.radonc.2014.01.001. Epub 2014 Jan 28.
Abstract | Related citations



Suardi N, Gandaglia G, Gallina A, Di Trapani E, Scattoni V, Vizziello D, Cucchiara V, Bertini R, Colombo R, Picchio M, Giovacchini G, Montorsi F, Briganti A.
Long-term Outcomes of Salvage Lymph Node Dissection for Clinically Recurrent Prostate Cancer: Results of a Single-institution Series with a Minimum Follow-up of 5 Years.
Eur Urol. 2014 Feb 18. pii: S0302-2838(14)00130-4. doi: 10.1016/j.eururo.2014.02.011. [Epub ahead of print]
Abstract | Related citations


Wang D, Ho A, Hamilton AS, Wu XC, Lo M, Fleming S, Goodman M, Thompson T, Owen J.
Type and dose of radiotherapy used for initial treatment of non-metastatic prostate cancer.
Radiat Oncol. 2014 Feb 5;9:47. doi: 10.1186/1748-717X-9-47.
Abstract | Full text | Related citations


Advanced PCa

Beardo-Villar P, Ledo-Cepero MJ, Gavira-Moreno R, Soto-Delgado M, Soto-Villalba J, Alvarez-Ossorio JL, Juárez-Soto A.
Initial experience with abiraterone acetate in patients with castration-resistant prostate cancer.
Actas Urol Esp. 2014 Jan 28. pii: S0210-4806(13)00388-4. doi: 10.1016/j.acuro.2013.11.004. [Epub ahead of print] English, Spanish.
Abstract | Related citations


de Bono JS, Piulats JM, Pandha HS, Petrylak DP, Saad F, Aparicio LM, Sandhu SK, Fong P, Gillessen S, Hudes GR, Wang T, Scranton J, Pollak MN.
Phase II randomized study of figitumumab plus docetaxel and docetaxel alone with crossover for metastatic castration-resistant prostate cancer.
Clin Cancer Res. 2014 Apr 1;20(7):1925-34. doi: 10.1158/1078-0432.CCR-13-1869. Epub 2014 Feb 17.
Abstract | Related citations


Heidenreich A, Bracarda S, Mason M, Ozen H, Sengelov L, Van Oort I, Papandreou C, Fossa S, Hitier S, Climent MA; European investigators.
Safety of cabazitaxel in senior adults with metastatic castration-resistant prostate cancer: results of the European compassionate-use programme.
Eur J Cancer. 2014 Apr;50(6):1090-9. doi: 10.1016/j.ejca.2014.01.006. Epub 2014 Jan 31.
Abstract | Related citations


Horgan AM, Seruga B, Pond GR, Alibhai SM, Amir E, De Wit R, Eisenberger MA, Tannock IF.
Tolerability and efficacy of docetaxel in older men with metastatic castrate-resistant prostate cancer (mCRPC) in the TAX 327 trial.
J Geriatr Oncol. 2014 Apr;5(2):119-26. doi: 10.1016/j.jgo.2013.12.001. Epub 2014 Jan 2.
Abstract | Related citations


Lawrenson R, Obertová Z, Brown C, Fong P, Tyrie L, Scott N, Holmes M.
The Use of Androgen Deprivation Therapy (ADT) and Chemotherapeutic Agents in New Zealand Men with Prostate Cancer.
J Cancer. 2014 Feb 14;5(3):214-20. doi: 10.7150/jca.8152. eCollection 2014.
Abstract | Full text | Related citations


Mostaghel EA.
Abiraterone in the treatment of metastatic castration-resistant prostate cancer.
Cancer Manag Res. 2014 Jan 28;6:39-51. eCollection 2014.
Abstract | Full text | Related citations


Nadal R, Taplin ME, Bellmunt J.
Enzalutamide for the treatment of prostate cancer: results and implications of the AFFIRM trial.
Future Oncol. 2014 Feb;10(3):351-62. doi: 10.2217/fon.13.275.
Abstract | Related citations


Tosco L, Van Poppel H.
Prostate cancer: The role of local therapy for metastatic prostate cancer.
Nat Rev Urol. 2014 Mar;11(3):134-5. doi: 10.1038/nrurol.2014.33. Epub 2014 Feb 25.
Abstract | Related citations


Zhang C, Jing T, Wang F, Gao X, Xu C, Sun Y.
Chemotherapy Plus Estramustine for Management of Castration-Resistant Prostate Cancer: Meta-Analysis of Randomized Controlled Trials.
Actas Urol Esp. 2014 Apr;38(3):184-191. doi: 10.1016/j.acuro.2013.07.010. Epub 2014 Feb 5.
Abstract | Related citations


Treatment comparison

Localized PCa

Gandaglia G, Abdollah F, Hu J, Kim S, Briganti A, Sammon JD, Becker A, Roghmann F, Graefen M, Montorsi F, Perrotte P, Karakiewicz PI, Trinh QD, Sun M.
Is Robot-Assisted Radical Prostatectomy Safe in Men with High-Risk Prostate Cancer? Assessment of Perioperative Outcomes, Positive Surgical Margins, and Use of Additional Cancer Treatments.
J Endourol. 2014 Mar 24. [Epub ahead of print]
Abstract | Related citations


Magheli A, Busch J, Leva N, Schrader M, Deger S, Miller K, Lein M.
Comparison of surgical technique (open vs. laparoscopic) on pathological and long term functional outcomes following radical prostatectomy.
BMC Urol. 2014 Feb 7;14:18. doi: 10.1186/1471-2490-14-18.
Abstract | Full text | Related citations



Suardi N, Gandaglia G, Gallina A, Di Trapani E, Scattoni V, Vizziello D, Cucchiara V, Bertini R, Colombo R, Picchio M, Giovacchini G, Montorsi F, Briganti A.
Long-term Outcomes of Salvage Lymph Node Dissection for Clinically Recurrent Prostate Cancer: Results of a Single-institution Series with a Minimum Follow-up of 5 Years.
Eur Urol. 2014 Feb 18. pii: S0302-2838(14)00130-4. doi: 10.1016/j.eururo.2014.02.011. [Epub ahead of print]
Abstract | Related citations


Rane A.
Surgery or radiotherapy for prostate cancer?
BMJ. 2014 Feb 26;348:g1580. doi: 10.1136/bmj.g1580.
Abstract | Related citations



Sooriakumaran P, Nyberg T, Akre O, Haendler L, Heus I, Olsson M, Carlsson S, Roobol MJ, Steineck G, Wiklund P.
Comparative effectiveness of radical prostatectomy and radiotherapy in prostate cancer: observational study of mortality outcomes.
BMJ. 2014 Feb 26;348:g1502. doi: 10.1136/bmj.g1502.
Abstract | Full text | Related citations


Wilt TJ.
Management of low risk and low PSA prostate cancer: long term results from the prostate cancer intervention versus observation trial.
Recent Results Cancer Res. 2014;202:149-69. doi: 10.1007/978-3-642-45195-9_18.
Abstract | Related citations


Treatment complications

Musunuru H, Mason M, Murray L, Al-Qaisieh B, Bownes P, Smith J, Franks K, Carey B, Bottomley D, Henry AM.
Second primary cancers occurring after I-125 brachytherapy as monotherapy for early prostate cancer.
Clin Oncol (R Coll Radiol). 2014 Apr;26(4):210-5. doi: 10.1016/j.clon.2014.01.006. Epub 2014 Feb 6.
Abstract | Related citations


Murray L, Henry A, Hoskin P, Siebert FA, Venselaar J; PROBATE group of GEC ESTRO.
Second primary cancers after radiation for prostate cancer: a systematic review of the clinical data and impact of treatment technique.
Radiother Oncol. 2014 Feb;110(2):213-28. doi: 10.1016/j.radonc.2013.12.012. Epub 2014 Jan 30.
Abstract | Full text | Related citations


Rescigno P, di Lorenzo G.
The potential detrimental effect of corticosteroids in prostate cancer.
Future Oncol. 2014 Feb;10(3):325-7. doi: 10.2217/fon.13.270.
Abstract | Full text | Related citations


Treatment decision making

Kim SP, Gross CP, Nguyen PY, Smaldone MC, Thompson RH, Shah ND, Kutikov A, Han LC, Karnes RJ, Ziegenfuss JY, Tilburt JC.
Specialty bias in treatment recommendations and quality of life among radiation oncologists and urologists for localized prostate cancer.
Prostate Cancer Prostatic Dis. 2014 Feb 25. doi: 10.1038/pcan.2014.3. [Epub ahead of print]
Abstract | Related citations



Quon H, Suderman D, Guilbert K, Lambert P, Bucher O, Ong A, Chowdhury A.
Population-based referrals for adjuvant radiotherapy after radical prostatectomy in men with prostate cancer: impact of randomized trials.
Clin Genitourin Cancer. 2014 Feb;12(1):e1-5.
Abstract | Related citations